Last reviewed · How we verify
TQB2450+Anlotinib
TQB2450 is a tyrosine kinase inhibitor, and Anlotinib is a vascular endothelial growth factor receptor (VEGFR) inhibitor.
TQB2450 is a tyrosine kinase inhibitor, and Anlotinib is a vascular endothelial growth factor receptor (VEGFR) inhibitor. Used for Non-small cell lung cancer, Gastric cancer.
At a glance
| Generic name | TQB2450+Anlotinib |
|---|---|
| Sponsor | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| Drug class | Tyrosine kinase inhibitor |
| Target | VEGFR, PDGFR, c-Kit |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
TQB2450 targets multiple tyrosine kinases, including VEGFR, PDGFR, and c-Kit, while Anlotinib specifically inhibits VEGFR. This dual inhibition is thought to suppress tumor growth and angiogenesis.
Approved indications
- Non-small cell lung cancer
- Gastric cancer
Common side effects
- Hypertension
- Diarrhea
- Fatigue
- Nausea
- Vomiting
Key clinical trials
- Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus. (PHASE2)
- A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer (PHASE2)
- A Single-arm, Multicenter Exploratory Clinical Trial of Anlotinib Combined With TQB2450 and the SOX Regimen as First-line Treatment for Advanced Gastric Cancer With Low PD-L1 Expression (PHASE2)
- Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCC (PHASE2)
- A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer (PHASE3)
- Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung Cancer (PHASE2)
- TQB2450 Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma (NA)
- A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TQB2450+Anlotinib CI brief — competitive landscape report
- TQB2450+Anlotinib updates RSS · CI watch RSS
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. portfolio CI